BCL2 and neoplasm: Moreover, Myr-NE tumor samples showed a significant increase in Bax/Bcl2 ratio by 2.86 ± 0.58 fold, which confined to 1.34 ± 0.101 fold in Myricetin tumor, compared with control further confirming the enhanced activation of pro-apoptotic proteins in Myr-NE tumor cells (Figure 5F).